Clinical applications

Rarity superRCA is an ultrasensitive multiplex assay for detecting rare nucleic acid sequences in biological samples with read-out on standard flow cytometers.

The assay is highly accessible and easily transferable as flow cytometers and thermal cyclers are standardized tool already found in most clinical laboratories and the acquisition protocols can be standardized for this assay. No need for capital investment, just transfer and go!

Measurable Residual Disease (MRD)


MRD or post treatment disease surveillance offers the promise of improved treatment and resistance monitoring and better patient risk stratification but have been limited by low sensitivity and impractical turn-around times for sampling and analysis.

The superRCA assays offers ultra-high sensitivity for detection of multiple mutation targets simultaneously, in a panel or individually. This enables multiplex detection of also low levels of ctDNA, allowing for the possibility of earlier detection of mutations.

The short turn-around-times (TAT) of the assay and easy analysis of data facilitates fast response times, contributing to fast decision making.

Acute Myeloid Leukemia

Colorectal Cancer

Lung Cancer

Liquid Biopsy

Liquid Biopsy and tissue rescue_Rarity Bioscience

Tissue biopsy is the current gold standard, but it is not always available, or it can be very difficult to obtain. It is also not practical to routinely use tissue samples for follow-up of patients.

Rarity Bioscience’s superRCA assay offers the ultra-high sensitivity detection of multiple mutation targets simultaneously needed to analyze both genomic and cell-free DNA in liquid biopsies and thereby minimizes the need for invasive and demanding sampling.

The utilization of very short nucleic acid detection sequences in the superRCA assay also gives good performance in liquid biopsies prone to nucleosome fragmentation. 

The short turn-around-times (TAT) of the assay makes it more practical for frequent patient sampling and MRD.

Clinical Trials

Mutation analysis using genomic and cell-free DNA in both solid and liquid biopsies have become an integral part of biomarker assessment in both pharma development and clinical testing, and aid in accurately understanding the hosts clinical status. It can also be used to better define inclusion criteria in clinical studies and patient stratification to treatment groups, and then aid in monitoring disease progression and improve risk or outcome stratification.

Beyond offering performance improvements related to ultra-high sensitivity and detection of multiple mutation targets simultaneously in also liquid biopsies, the superRCA assay technology uses standard issue flow cytometers for sample analysis that can be found at many labs and CROs. This makes initial investment low and makes assay transfer and validation easy and there is little need to train the staff on new data analysis software.